Feasibility and Performance of a Point-of-Care Hepatitis C RNA Assay in a Community Supervision Cohort

Leah Harvey; Brendan Jacka; Lauri Bazerman; Aurielle Thomas; Marc Moody; Risha Irvin; Curt G Beckwith

doi:10.1001/jamanetworkopen.2024.38222

Feasibility and Performance of a Point-of-Care Hepatitis C RNA Assay in a Community Supervision Cohort

JAMA Netw Open. 2024 Oct 1;7(10):e2438222. doi: 10.1001/jamanetworkopen.2024.38222.

Authors

Leah Harvey^{1

2}, Brendan Jacka³, Lauri Bazerman², Aurielle Thomas², Marc Moody⁴, Risha Irvin⁵, Curt G Beckwith^{1

2}

Affiliations

¹ Division of Infectious Diseases, The Warren Alpert School of Medicine at Brown University, Providence, Rhode Island.
² Division of Infectious Diseases, Department of Medicine, The Miriam Hospital, Providence, Rhode Island.
³ The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
⁴ Rhode Island Department of Corrections, Pawtucket.
⁵ Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland.

No abstract available

Plain language summary

This cross-sectional study examines the feasibility and clinical performance of a fingerstick point-of-care hepatitis C virus (HCV) RNA assay in a community supervision (probation or parole) setting.

MeSH terms

Adult
Cohort Studies
Feasibility Studies*
Female
Hepacivirus* / genetics
Hepatitis C* / diagnosis
Humans
Male
Middle Aged
Point-of-Care Systems
Point-of-Care Testing
RNA, Viral* / analysis

Substances

RNA, Viral